Biotech

aria technology

Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video

Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX Chris Bunka, CEO and Chairman of Lexaria Bioscience, speaks about the Company's proprietary drug delivery technology, DehydraTECH™.


If you cannot view the video above, please visit:

https://b-tv.com/lexaria-bioscience-proprietary-drug-delivery-technology-ceo-clip-90sec/

Lexaria Bioscience is being featured on BNN Bloomberg on May 1st - May 2nd.

Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX)
www.lexariabioscience.com

About CEO Clips:

CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 second video profiles broadcast on national TV and online via 15 top financial sites including: Thomson Reuters, Bloomberg, Yahoo! Finance and Stockhouse.com.

BTV - Business Television/CEO Clips Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81943

News Provided by Newsfile via QuoteMedia

The Conversation (0)

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

New LUMAKRAS ® (sotorasib) Data From First Study Evaluating Intracranial Efficacy of a KRAS G12C Inhibitor Versus Docetaxel in Treated KRAS G12C-Mutated Advanced NSCLC

Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE ® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® IN PSORIATIC ARTHRITIS AT EULAR 2023

MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis Patients

Exploratory Analysis Examines Effects of Otezla on Cardiometabolic Parameters

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Komo Plant-Based Foods Inc.

Komo Plant Based Foods Inc. Announces Expanded Distribution Through Koyo Foods Inc.

Komo Plant Based Foods Inc. (CSE: YUM) (OTC Pink KOMOF) (FRA:9HB) ("Komo" or the "Company"), a premium plant-based food company, is proud to announce its alliance with Koyo Foods Inc., one of the largest health food distributors in Eastern Canada.

Koyo Foods Inc., renowned for its impressive range of over 2000 health and wellness products, will now include Komo's award-winning plant-based comfort foods in its distribution portfolio. This alliance marks an exciting milestone for Komo, expanding its reach to more consumers in Eastern Canada.

Keep reading...Show less

AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT

Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday May 31, 2023. David M. Reese M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

  • Special Shareholder Meeting to be Held in July 2023

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp. (" SpinCo "), a wholly-owned subsidiary of the Company (the " Arrangement Agreement ") pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the " SpinCo Assets "), will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act (British Columbia) (the " Arrangement ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has contracted Atheln Inc. (" Atheln "), a leading US consulting firm, to bolster and facilitate Sirona's business activities. This strategic initiative comes at an opportune time, as Sirona prepares for the highly anticipated BIO International 2023 conference in Boston, where it will showcase its groundbreaking anti-aging compound, TFC-1326 . Under the guidance of Monica Alfaro Welling Atheln will spearhead the project team to ensure the success of Sirona's meetings during the conference.

The primary focus of the contract is to meticulously prepare for the BIO International conference, where Sirona aims to establish valuable partnerships for the development and commercialization of TFC-1326. Recognizing the significance of these meetings, the collaboration with Atheln aims to maximize the probability of success. Sirona's team has secured numerous meetings with organizations and companies that possess complementary resources, capabilities, and a strategic interest in partnerships.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×